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Abstract 
Calcinosis cutis is an uncommon disorder characterized by the progressive deposition of 
crystals of calcium phosphate (hydroxyapatite) in the skin in various areas of the body. It 
is classified into four types according to etiology, namely as dystrophic if calcium and 
phosphorus levels are normal and tissue damage is present, as idiopathic if calcium and 
phosphorus levels are normal and no tissue damage is present, or as metastatic if there is 
hypercalcemia or hyperphosphatemia. Medical and surgical treatments are options to 
cure calcinosis cutis. Medical therapy is not very effective. Surgical excision has shown to 
be beneficial, as it can provide a symptomatic relief. However, since calcinosis cutis limits 
are not always well defined, a recurrence of the lesions may occur. We dealt with a very 
rare form of calcinosis cutis in a healthy 6-year-old girl. There was no evidence of 
connective tissue disorder or abnormal mineral metabolism. Hence, she was diagnosed 
as idiopathic calcinosis cutis and, although calcifications in idiopathic cutis are most 
commonly localized to one area, our patient unusually exhibited widespread calcific 
deposits. Although the existing lesions showed slow improvement, systemic 
pamidronate therapy was effective in preventing the occurrence of new lesions. Surgical 
excision proved to be an effective and successful treatment. This report aims to raise 
doctors’ awareness on the presentation, etiopathogenesis, and course of the relatively 
rare idiopathic calcinosis cutis.  
 
Introduction 
Calcinosis cutis is an uncommon disorder which results in progressive deposition of 
insoluble calcium salts (crystals of calcium phosphate, hydroxyapatite) in the skin. 
Calcium deposits may be intracutaneous, subcutaneous, fascial and intramuscular, and 
sometimes involve visceral organs [1]. The course can be identified in most of the  
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circumstances by clinical evaluation and investigations. But in some cases, the etiology 
cannot be found out even after extensive work-up. Work-up in a patient diagnosed with 
calcinosis cutis includes a careful history of possible trauma or repetitive exposure to 
calcium salts. The history and physical examination should also elicit any sign or 
symptom of possible collagen vascular disorders. X ray examination or sonography of the 
extremities and trunk for dense shadows due to calcium is important. Biopsy plays an 
important role. 
We herein report a child with calcinosis cutis who unusually exhibited widespread 
calcific deposits with an idiopathic etiology. 
Case Report 
A 6-year-old female child presented to our center complaining of multiple subcutaneous nodules 
that had progressed to pustules and ulcers with purulent discharge, which had started about 2 years ago 
on her hip and subsequently spread progressively to her arms, elbows and knees. Her past medical 
history revealed an operation in another center because of tendonitis (histopathologic diagnosis) in both 
knees at age 2 1/2 years. There was no more information. There was no family history of similar lesions. 
At the time of presentation, the patient was otherwise healthy and had no complaints of joint pain, 
muscle weakness, skin rashes, Raynaud’s phenomenon, dysphagia or dyspnea. She was not on any 
medication and had no known drug allergies. 
On physical examination, we found numerous firm yellowish-white subcutaneous nodules 
approximately 3–7 cm in diameter on her trunk, arms, elbows, knees and legs bilaterally (fig. 1). Some 
of these lesions were soft and fluctuant and had a sinus overdischarging chalky white material of 2 years 
duration, while some comprised scar tissue. The systemic evaluation including the neurological 
examination were normal, and the patient had no symptoms such as muscle weakness or stiffness. 
The laboratory investigations revealed within normal serum calcium (10 mg/dl, normal: 8.5–10.3 
mg/dl), phosphorus (4.9 mg/dl, normal: 3.0–6.0 mg/dl) as well as serum 25-hydroxy vitamin D (54 
ng/dl, normal: 17–54 ng/dl), parathormone (PTH) (25 pg/dl, normal: 11–54 pg/dl) and osteocalcine (10 
mg/dl, normal: 8.5–10.3 mg/dl) levels done on different occasions. Biochemical examinations gave 
normal results for complete hemogram, erythrocyte sedimentation rate, blood sugar, uric acid, 
electrolyte, liver function and kidney function tests. Routine urine examination was normal. 24-hour 
urinary calcium (10 mg/dl, normal: 8.5–10.3 mg/dl) and phosphorus (0.36 g, normal: 0.4–1.3 g/day) 
excretion were normal. 
Screening tests for collagen vascular disease, including ANA, anti-DNA, anti-SM, ANCA, 
rheumatoid arthritis (RA) test, serum C3, C4 and CH50 levels were within normal limits. Tuberculin 
skin test was negative. Staphylococcus aureus was grown in bacteriological cultures of the purulent 
discharge. 
Radiological examination showed that there was no bone pathology and no joint involvement, but 
widespread extensive amorphous calcifications in the soft tissues around joints. Ultrasonography 
showed that the calcifications were located in fat tissue under the skin, but not in deeper tissues or 
muscles. Investigations showed no indications of internal malignancy. Whole body tomography and 
bone marrow aspiration was normal. 
Scintigraphic research showed no pathology in the thyroid and parathyroid. Hematoxylin- and 
eosin-strained histologic sections from excisional biopsies of lesions demonstrated deep cutaneous 
and/or subcutaneous deposits of homogenous material suggestive of calcium deposition, consistent with 
calcinosis cutis. On the basis of clinical, radiological and histopathologic data, a diagnosis of idiopathic 
calcinosis cutis universalis was made. 
At the time of presentation, systemic therapy, such as cyclic intravenous pamidronate disodium 
(Aredia), was administrated every 2 months, 1 mg/kg/day for 3 days. In the follow-up time, some 
nodules became ulcerated and were complicated by repeated bacterial infections; some nodules required 
large surgical excisions and the dense chalk-like materials were removed successfully from the deposits 
in the hip and elbows without recurrence. Although the patient showed good tolerance, 2 years ago, 4-
year follow-up revealed minimal changes in the current lesions with this treatment. Consequently, 
pamidronate disodium was discontinued and the girl was started on prednisolone. Despite a trial of 3  
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months with oral prednisolone (1 mg/kg/day) her condition began to deteriorate. She developed new 
lesions in the skin on multiple parts of the body (fig. 2), and abdominal hardness was noticed. Disclosed 
X ray and tomography of the abdomen showed that calcifications were located in the fat and muscle 
tissue under the skin, which were more evident at the right side, but not in deeper tissues. So, oral 
prednisolone was discontinued and intravenous pamidronate disodium was started in the same dose. 
Surgical excision of 3 selected fluctuant, subcutaneous nodules was performed due to severe pain and 
impaired mobility associated with the calcification. Recurrence did not occur. On 1-year follow-up, the 
current lesions had become smaller and no new lesions had appeared. After follow-up examinations 
over the last 2 years, the patient is still on intravenous pamidronate disodium. No new lesions have 
appeared and most of the old lesions have ulcerated and cicatrized (fig. 3). 
Discussion 
Calcinosis cutis has been described rarely in children [2]. It is due to a variety of 
etiologies and classically, it can be classified as metastatic, dystrophic and idiopathic types 
[3]. The pathogenesis of this condition is unknown and probably multifactorial. In 
metastatic calcinosis cutis, spontaneous deposition of calcium and phosphate in normal 
tissues is present due to increased serum calcium and/or phosphate levels or both. 
Calcium treatment, primary hyperparathyroidism, hypervitaminosis D, renal failure, 
milk-alkali syndrome, destructive bone disease, sarcoidosis and paraneoplastic 
hypercalcemia are some of the factors involved in increased serum calcium levels [4]. 
Dystrophic calcinosis cutis is the most common form and it may provide a history of an 
underlying disease associated with normal serum calcium and phosphate levels. 
Connective tissue disorders (including juvenile dermatomyositis, systemic lupus 
erythematosus, and systemic scleroderma), infections and local tissue traumas can be 
encountered in such primary pathologies [5, 6]. 
Idiopathic calcinosis cutis is a rare form and occurs in apparently normal tissue in the 
absence of known tissue injury, systemic metabolic effect or collagen vascular disease and 
percutaneous exposure to calcium [7]. The ultrastructural morphology of localized skin 
calcifications without associated diseases and with normal serum calcium and phosphate 
ion values is not entirely understood. Calcium and phosphate excretion may be low. Our 
patient was not considered to have metastatic calcification because the investigations of 
biochemical and radiological findings ruled out indications of any primary systemic 
disease. Moreover, serum calcium and phosphate levels were within normal limits. There 
was no evidence of primary skin injury, infection or connective tissue disorder known to 
cause dystrophic calcification, and screening tests for collagen vascular disease were 
negative. No causative factor is identifiable and, thus, the diagnosis of idiopathic 
calcinosis cutis was made in our case. Although calcification in idiopathic cutis is most 
commonly localized to one area, our patient unusually exhibited widespread calcified 
deposits. In recent reports, it was suggested that idiopathic calcinosis cutis lesions may be 
early findings of connective tissue disorders. Wananukul et al. [8] reported two cases of 
calcinosis cutis with onset years before other clinical manifestations of juvenile 
dermatomyositis were diagnosed. We suggested that the beginning of calcinosis started at 
age 2 1/2, with tendonitis, so our patient had a long history of calcinosis. She may be an 
extensive calcinosis cutis case with onset years before other clinical manifestations of a 
systemic connective tissue disorder, but, so far, during the long follow-up time, there has 
been no evidence of another disorder. 
A variety of drugs, including bisphosphonates, intralesional corticosteroids, aluminum 
hydroxide, warfarin, and diltiazem, and low calcium diet have been tried with less-than-
ideal success [9, 10]. In idiopathic calcinosis cutis, surgical excision is an effective 
treatment and provides an accurate diagnosis [11], but can be considered as a last resort.  
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However, excision or drainage should be limited to very carefully selected sites where pain 
and disability outweigh the risk of recurrence and further calcification due to surgical 
trauma. Spontaneous resolution of lesions has also been reported in cases of idiopathic 
calcinosis cutis in the scrotum and mons pubis. Our case is another observation which 
reports a noteworthy outcome of cutaneous lesions subsequent to treatment with 
pamidronate disodium (a nitrogen containing bisphosphonate), and surgery. We can 
consider pamidronate treatment successful because, although the clinical examination of 
the lesions revealed very slow regression in agreement with the literature, no new lesions 
occurred during therapy and severe progression of new lesions were noticed after 
cessation of pamidronate. In contrast to their use in osteopathy and hypercalcemia, there 
have been few reports on the use of bisphosphonates in conditions associated with 
calcinosis in pediatric practice, such as dermatomyositis, fibrodysplasia ossificans 
progressiva and scleroderma, and where they induced a favorable outcome. One report of 
a 6-year-old child with extensive subcutaneous calcification secondary to juvenile 
dermatomyositis documents the successful response of oral use of a bisphosphonate such 
as alendronate [12]. 
The primary bisphosphonate mechanism of action was the inhibition of osteoclastic 
bone resorption and the decrease in bone resorption [13, 14]. Some previous reports 
regarding the use of bisphosphonates in the treatment of ectopic calcifications also 
showed an anti-inflammatory effect and a significant reduction in the size of calcifications 
[15, 16]. Bisphosphonates are known to have a strong effect on macrophage cell lineage, 
causing selective destruction of macrophages and inhibiting macrophage 
proinflammatory cytokine production (IL-1β, IL-6, TNF-α) and growth. The effect of 
bisphosphonates on macrophages may explain the reduction of inflammation in the 
calcified areas. Long-term treatment with pamidronate has resulted in increased calcium 
balance, catch-up linear growth before puberty, and no mineralization defects on bone 
biopsy. However, bone turnover is suppressed during therapy, and the impact of this in 
young infants and children is not known. However, our patient, who received 
pamidronate for more than 6 years, reportedly had normal growth and development, 
calcium serum concentrations, and urinary excretion at follow-up visits [14]. 
Excisions were performed carefully in 3 selected fluctuant, subcutaneous nodules due 
to severe pain and impaired mobility in these places in our patient. Recurrence did not 
occur. Perhaps the bisphosphonate therapy may have some role in this. Currently, the 
patient is undergoing systemic pamidronate treatment and is still under our observation. 
In summary, we highlight the importance of identification of this rare but innocent 
disease and the use of bisphosphonates and surgical procedures in suitable patients 
without recurrence. A better understanding of the processes of calcinosis cutis by new 
case reports will lead to therapies which help to retard or improve this phenomenon and 
will probably have an important impact on patient morbidity. 
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Fig. 1. Photograph showing the multiple firm erythematous-whitish nodules at the hips, arms and 
knees. 
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Fig. 2. Photograph of patient’s hips, elbows and knees demonstrating multiple subcutaneous nodules 3 
months after prednisolone start. 
 
 
 
Fig. 3. Marked regression of the lesions in the hips (a), elbows (b) and knees (c) after 6 years of 
follow-up. 
 
  
Case Rep Dermatol 2009;1:16–22 
DOI: 10.1159/000227285 
Published online: August 28, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
22
References 
1  Walsh JS, Fairley JA: Calcifying disorders of the skin. J Am Acad Dermatol 
1995;33:693–706. 
2  Rodriguez-Cano L, Garcia-Patos V, Creus M, et al: Childhood calcinosis cutis. 
Pediatr Dermatol 1996;13:114–117. 
3  Puvabanditsin S, Garrow E, Titapiwatanakun R, Getachew R, Patel JB: Severe 
calcinosis cutis in an infant. Pediatr Radiol 2005;35:539–542.  
4  Zouboulis CC, Blume-Peytaui U, Lennert T: Fulminant metastatic calcinosis with 
cutaneous necrosis in a child with end-stage renal disease and tertiary 
hyperparathyroidism. Br J Dermatol 1996;135:617–622. 
5  Lobo IM, Machado S, Teixeira M, Selores M: Calcinosis cutis: a rare feature of 
adult dermatomyositis. Dermatol Online J 2008;14:10. 
6  Tristano AG, Villarroel JL, Rodríguez MA, Millan A: Calcinosis cutis universalis 
in a patient with systemic lupus erythematosus. Clin Rheumatol 2006;25:70–74.  
7  Guermazi A, Grigoryan M, Cordoliani F, Kérob D: Unusually diffuse idiopathic 
calcinosis cutis. Clin Rheumatol 2007;26:268–270.  
8  Wananukul S, Pongprasit P, Wattanakrai P: Calcinosis cutis presenting years 
before other clinical manifestations of juvenile dermatomyositis: report of two 
cases. Australas J Dermatol 1997;38:202–205. 
9  Rodan GA: Mechanisms of action of bisphosphonates. Annu Rev Pharmacol 
Toxicol 1998;38:375–388. 
10  Prica PA, Omid N, Than TN, Williamson MK: The amino bisphosphonate 
ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. 
Calcif Tissue Int 2002;71:356–363. 
11  Dubois LA, Gray DK, Tweedie EJ: Surgical images: soft tissue. Calcinosis cutis. 
Can J Surg 2007;50:217–218. 
12  Mukamel M, Horev G, Mimouni M: New insight into calcinosis of juvenile 
dermatomyositis: a study of composition and treatment. J Pediatr 2001;138:763–
766. 
13  Rodan GA: Mechanisms of action of bisphosphonates. Annu Rev Pharmcol 
Toxicol 1998;38:375–388. 
14  Russell RG: Bisphosphonates: mode of action and pharmacology. Pediatrics 
2007;119(suppl 2):S150–S162. 
15  Monteforte P, Rovetta G: Change in size of periarthritis calcifications in patients 
with painful shoulder treated with injectable disodium-clodronate. Int J Clin 
Pharmacol Res 2002;22:7–12. 
16  Phanish MK, Kallarackal G, Ravanan R, Lawson TM, Baboolal K: Tumoral 
calcinosis associated with pyrexia and systemic inflammatory response in a 
haemodialysis patient: successful treatment using intravenous pamidronate. 
Nephrol Dial Transplant 2000;15:1691–1693. 
 